

Data Supplement S1: Ongoing Clinical Trials Evaluating Use of HCQ/CQ as Treatment for COVID-19

Study	NCT Identifier	Organization/ Funding	Design/Current progress	Particip ants	Intervention	Control	Primary Outcome	Comments
Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid)	NCT04328272	Ayub Teaching hospital	Single blind RCT/Not yet recruiting	75	1. HCQ 1200mg LD, 800mg D2-7 2. HCQ 1200mg LD, 800mg D2-7 or + Azithromycin 500mg LD, 250mg D2-7	Placebo	● National Early Warning Score (NEWS)	
ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease	NCT04329611	University of Calgary	Double Blind RCT/Not yet recruiting	1660	HCQ 800mg LD, 200mg BID D2-D5	Placebo	● Hospitalization and mechanical ventilation status in 30 days	
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease (COMIHY)	NCT04340544	University Hospital Tuebingen	Quadruple blind RCT/Not yet recruiting	2700	HCQ 600 mg D1-D7	Placebo	● Different in time to resolution of clinical symptoms as assessed by daily self-assessment in 28 days	
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS)	NCT04329832	Intermountain Health Care, Inc./ University of Utah	Open Label RCT/Recruiting	300	HCQ 800mg LD, 200 BID D2-D5	Azithromycin 500mg LD, 250mg D2-D5	● COVID ordinal outcomes scale at 14 days	
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah with COVID-19 (HyAzOUT)	NCT04334382	Intermountain Health Care, Inc./University of Utah	Open Label RCT/Recruiting	1550	HCQ 800mg LD, 200mg BID D2-D5	Azithromycin 500mg LD, 250mg D2-D5	● Hospitalization status in 14 days	
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with Mild Coronavirus Disease (COVID-19)	NCT04307693	Asan Medical Center	Open Label RCT/Recruiting	1500	1. Lopinavir/ritonavir 200mg/100mg QID D1-D7 2. Hydroxychloroquine 200mg QID D1-D7	Supportive care	● Viral load assessed D3 D5 D7 D10 D14 D18	
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19	NCT04336332	Rutgers, The State University of New Jersey	Open Label RCT/Not yet recruiting	160	1. HCQ 200 TID D1-D10 + Azithromycin 500mg LD, 250mg D2-D5 2. HCQ 200 TID D1-D10	Supportive care but if sick, HCQ 200mg TID D1-D10	● Viral load assessed D0 D3 D6	
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA)	NCT04315896	National Institute of Respiratory Diseases	Quadruple blind RCT/Not yet recruiting	500	HCQ 200mg BID D1-D10	Placebo	● All-cause hospital mortality as 120 days	
Hydroxychloroquine for the Treatment of Patients with Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	NCT04323631	Rambam Health Care Campus	Open label RCT/Not yet recruiting	1116	HCQ 800mg LD, 200mg BID D2-D10	Supportive care	● Number of patients developing severe infection or death at 28 days	
The PATCH Trial (Prevention and Treatment of COVID-19 With Hydroxychloroquine)	NCT04329923	University of Pennsylvania	Triple blind RCT/Not yet recruiting	400	Cohort 1) Those quarantined at home: HCQ 400mg BID D1-D14, Cohort 2) Those hospitalized: HCQ 600mg BID D1-D14 Cohort 3) Heath care workers: HCQ 600mg daily 2 months	Cohort 1) Placebo, crossover allowed in 7 days Cohort 2) HCQ 600mg D1-D7 Cohort 3) Placebo,	● Median release from quarantine time in cohort 1 ● Rate of hospital discharge in cohort 2 ● Rate of infection in cohort 3	Crossover study

Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	NCT04332094	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Instituto de Salud Carlos III	Open label RCT/Recruiting	276	Tocilizumab 324mg BID D1 + HCQ 400mg LD, 200mg BIG D2-D7 + Azithromycin 500mg D1-D3	crossover allowed if PCR+ HCQ 400mg LD, 200mg D2-D7 + Azithromycin 500mg D1-D3	<ul style="list-style-type: none"> In-hospital mortality Need for mechanical ventilation in the ICU 	
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients with Moderate to Severe COVID-19	NCT04329572	Prevent Senior Private Operadora de Saúde LTDA	Open label RCT/Not yet recruiting	400	HCQ 400mg LD, 400mg D2-D5 + Azithromycin 500mg D1-D5	NA	<ul style="list-style-type: none"> Evolution of acute respiratory syndrome Oxygen saturation Hemodynamic stability at 28 days 	No control group
Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT	NCT04338698	Federal Task Force on Science & Technology notified by Government of Pakistan, University of Health Sciences Lahore	Double blind RCT/Not yet recruiting	500	1: Azithromycin 500mg LD, 250mg D2-D5 2: Oseltamivir 75mg BID D1-D5 3: HCQ 200mg TID D1-D5 + Azithromycin 500mg LD, 250mg D2-D5 4: HCQ 200mg TID D1-D5+ Oseltamivir 75mg BID D1-D5 5: Oseltamivir 75mg BID D1-D5 + Azithromycin 500mg LD, 250mg D2-D5 6: HCQ 200mg TID D1-D5 + Oseltamivir 75mg BID D1-D5 + Azithromycin 500mg LD, 250mg D2-D5	HCQ 400mg LD, 200mg D2-D7 + Azithromycin 500mg D1-D3	<ul style="list-style-type: none"> Laboratory Result (negative PCR) on day 7 	No placebo group
Phase 2 Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARSCoV-2 Infection	NCT04335552	Duke University	Open label RCT/Not yet recruiting	500	1.HCQ 800mg LD, 600mg D2-D5 2. Azithromycin 500mg LD, 250mg D2-D5 3.HCQ 800mg LD, 600mg D2-D5 + Azithromycin 500mg LD, 250mg D2-D5	Supportive care	<ul style="list-style-type: none"> World Health Organization (WHO) ordinal scale measured at 14 days 	
Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19: A Randomized Control Trial	NCT04303299	Rajavithi Hospital	Open label RCT/Not yet recruiting	80	1. Ostamivir 300mg daily+ HCQ 800mg daily 2. Darunavir 400mg TID + Ritonavir 200mg daily + Ostamivir 300mg daily 3. Lopinavir 800mg daily + Ritonavir 200mg daily + Ostamivir 300mg daily 4. Lopinavir 800mg daily + Ritonavir 200mg daily + Ostamivir 300mg daily 5. Faviprivir 6000mg daily + Lopinavir 800mg daily+ Ritonavir 200mg daily 6. Derunavir 400mg TID + Ritonavir 200mg daily + Ostamivir 300mg daily + HCQ 800mg daily 7. Derunavir 400mg TID + Ritonavir 200mg daily + Favipiravir 6000mg daily + HCQ 800mg daily	Supportive care	<ul style="list-style-type: none"> SARS-CoV-2 eradication time at 24 weeks 	
COVID MED Trial - Comparison of Therapeutics for Hospitalized Patients Infected With SARSCoV-2	NCT04328012	Bassett Healthcare	Quadruple blind RCT/Not yet recruiting	4000	1. Lopinavir/Ritonavir 400mg/200mg BID for 5-14 days 2. HCQ 800mg LD, 200mg BID D1-d4 + Losartan 25mg for 5-14 days	Placebo	<ul style="list-style-type: none"> National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS) Hospital length of stay ICU stays Mechanical ventilation mortality 	
Hydroxychloroquine in Patients with Newly Diagnosed COVID-19 Compared to Standard of Care	NCT04334967	Providence Health & Services, Center for Outcomes Research and	Single blind RCT/Not yet recruiting	1250	HCQ 800mg LD, 200mg BID D2-D5	Vitamin C 2000mg D1, 1000mg D2-D5	<ul style="list-style-type: none"> Total hospitalization and total mechanical ventilation at 14 days 	

		Education, Providence Cancer Center, Earle A. Chiles Research Institute						
Outcomes Related to COVID-19 Treated with Hydroxychloroquine Among In-patients with Symptomatic Disease	NCT04332991	Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI)	Quadruple blind RCT/Not yet recruiting	510	HCQ 800mg LD, 200mg BID D2-D5	Placebo	<ul style="list-style-type: none"> COVID Ordinal Outcomes Scale at Day 15 	
A Study of Quintuple Therapy to Treat COVID-19 Infection	NCT04334512	Progena Biome	Open label RCT/Not yet recruiting	60	1. HCQ 2. Azithromycin 3. Vitamin C 4. Vitamin D 5. Zinc	NA	<ul style="list-style-type: none"> Successful treatment as determined by Negative Test and resolution of symptom at 4 weeks 	No control, unspecified drug doses
Safety and Efficacy of Hydroxychloroquine Associated with Azithromycin in SARSCoV2 Virus (Coalition Covid-19 Brasil II)	NCT04321278	Hospital Israelita Albert Einstein	Open label RCT/Not yet recruiting	440	1. HCQ 800mg LD, 200mg BID D2-D5 + Azithromycin 500mg QD 2. HCQ 800mg LD, 200mg BID D2-D5	NA	<ul style="list-style-type: none"> Evaluation of the clinical status after 15 days 	No control group
Hydroxychloroquine in Outpatient Adults With COVID-19	NCT04333654	Sanofi	Quadruple blind RCT/Not yet recruiting	210	HCQ for 9 days	Placebo	<ul style="list-style-type: none"> Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load Number of participants by PCR result status 	Unspecified drug doses
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomized Controlled Trial	NCT04339816	Masaryk Hospital Usti and Labem, University Hospital Pilsen	Triple blind RCT/Not yet recruiting	240	1. HCQ 800mg LD, 200mg BID D2-D5 + Azithromycin 500mg LD, 250mg D2-D5 2. HCQ 800mg LD, 200mg BID D2-D5	Placebo	<ul style="list-style-type: none"> Proportion of alive patients free off mechanical ventilation at 14 days 	
The Efficacy of Different Antiviral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2	NCT04321616	Oslo University Hospital	Open label RCT/Not yet recruiting	700	1. Remdesivir 200mg LD, 100mg D2-D10 2. HCQ 800mg LD, 400mg D2-D10 3. Remdesivir 200mg LD, 100mg D2-D10 + HCQ 800mg LD, 400mg D2-D10	NA	<ul style="list-style-type: none"> In-hospital mortality at 3 weeks 	No control group
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease	NCT04325893	University Hospital, Angers	Double blind RCT/Recruiting	1300	HCQ 800mg LD, 400mg D2-D14	Placebo	<ul style="list-style-type: none"> Number of deaths from any cause, or the need for intubation and mechanical ventilation at 14 days 	
Safety and Efficacy of Hydroxychloroquine Associated with Azithromycin in SARSCov-2 Virus	NCT04322123	Hospital do Coracao, Hospital Israelita Albert Einstein	Open label RCT/Recruiting	630	1. HCQ 400mg BID D1-D12 2. HCQ 400mg BID D1-D12 + Azithromycin 500mg D1-D7	Supportive care	<ul style="list-style-type: none"> Evaluation of the clinical status at 15 days 	
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	NCT04321993	Nova Scotia Health Authority,	Open label non-random clinical trial/Not yet recruiting	1000	1. Lopinavir/ritonavir 400mg/100mg BID D1-D10 2. HCQ 400mg BID D1-D10 3. Baricitinib 2mg D1-D10 4. Sarilumab 200mg once	Supportive care	<ul style="list-style-type: none"> Clinical status of subject at day 15 	Not randomized

Trial of Treatments for COVID-19 in Hospitalized Adults	NCT04315948	Institut National de la Santé Et de la Recherche Médicale	Open label RCT/Recruiting	3100	1. Remdesivir 200mg LD,100mg D1-D10 2. Lopinavir/ritonavir 400mg/100mg BID D1-D14 3. Lopinavir/ritonavir 400mg/100mg BID D1-D14 + Interferon β1a 44 μg 3 doses D1, D3, D5 4. HCQ 800mg LD, 400mg D1-D9	Supportive care	● Percentage of subjects reporting each severity rating on a 7-point ordinal scale in 15 days	
Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention	NCT04304053	Fundacio Lluita Contra la SIDA	Open label RCT/Recruiting	3040	Darunavir 800mg/cobicistat 150mg + HCQ 800mg LD, 400mg D2-D7	NA	● Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases at 14 days	No control group
Norwegian Coronavirus Disease 2019 Study	NCT04316377	University Hospital	Open label RCT/Recruiting	202	HCQ 400mg BID D1-D7	Supportive care	● Rate of decline in SARSCoV-2 viral load at 96 days	

Abbreviations: RCT: Randomized clinical trial, LD: Loading dose, D- Day-
Supportive care is bedrest, oxygen supplementation unless otherwise indicated.